X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs IPCA LABS - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA IPCA LABS GSK PHARMA/
IPCA LABS
 
P/E (TTM) x 67.4 28.9 233.5% View Chart
P/BV x 13.6 3.4 396.3% View Chart
Dividend Yield % 1.1 0.1 774.6%  

Financials

 GSK PHARMA   IPCA LABS
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
IPCA LABS
Mar-18
GSK PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs2,760695 396.9%   
Low Rs2,040400 510.0%   
Sales per share (Unadj.) Rs339.0260.2 130.3%  
Earnings per share (Unadj.) Rs41.419.0 218.3%  
Cash flow per share (Unadj.) Rs45.933.1 138.9%  
Dividends per share (Unadj.) Rs35.001.00 3,500.0%  
Dividend yield (eoy) %1.50.2 798.7%  
Book value per share (Unadj.) Rs242.9213.0 114.0%  
Shares outstanding (eoy) m84.70126.20 67.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.12.1 336.3%   
Avg P/E ratio x57.928.9 200.7%  
P/CF ratio (eoy) x52.316.6 315.5%  
Price / Book Value ratio x9.92.6 384.3%  
Dividend payout %84.55.3 1,603.2%   
Avg Mkt Cap Rs m203,28069,120 294.1%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m5,2347,359 71.1%   
Avg. sales/employee Rs ThNM2,477.4-  
Avg. wages/employee Rs ThNM555.2-  
Avg. net profit/employee Rs ThNM180.6-  
INCOME DATA
Net Sales Rs m28,71532,836 87.4%  
Other income Rs m545418 130.5%   
Total revenues Rs m29,26033,254 88.0%   
Gross profit Rs m5,0594,505 112.3%  
Depreciation Rs m3801,777 21.4%   
Interest Rs m2240 0.8%   
Profit before tax Rs m5,2222,905 179.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,892511 370.2%   
Profit after tax Rs m3,5082,394 146.5%  
Gross profit margin %17.613.7 128.4%  
Effective tax rate %36.217.6 206.0%   
Net profit margin %12.27.3 167.5%  
BALANCE SHEET DATA
Current assets Rs m21,81519,455 112.1%   
Current liabilities Rs m15,99910,076 158.8%   
Net working cap to sales %20.328.6 70.9%  
Current ratio x1.41.9 70.6%  
Inventory Days Days6498 65.0%  
Debtors Days Days1967 27.9%  
Net fixed assets Rs m12,47520,260 61.6%   
Share capital Rs m847252 335.6%   
"Free" reserves Rs m19,72626,633 74.1%   
Net worth Rs m20,57326,886 76.5%   
Long term debt Rs m62,340 0.3%   
Total assets Rs m39,47541,173 95.9%  
Interest coverage x2,612.013.1 19,946.0%   
Debt to equity ratio x00.1 0.3%  
Sales to assets ratio x0.70.8 91.2%   
Return on assets %8.96.4 139.0%  
Return on equity %17.18.9 191.5%  
Return on capital %26.210.8 243.9%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m56415,642 3.6%   
Fx outflow Rs m7,4294,884 152.1%   
Net fx Rs m-6,86510,759 -63.8%   
CASH FLOW
From Operations Rs m4,7283,411 138.6%  
From Investments Rs m-1,042-1,354 76.9%  
From Financial Activity Rs m-3,066-1,304 235.1%  
Net Cashflow Rs m620753 82.3%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 11.4 89.5%  
FIIs % 23.8 25.3 94.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 17.4 88.5%  
Shareholders   102,036 36,892 276.6%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   CIPLA  SANOFI INDIA  ALEMBIC PHARMA  SHASUN PHARMA  PFIZER  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Up Over 240 Points; Rupee Touches Record Low(12:30 pm)

After opening the day in the green, stock markets in India have continued their momentum and are presently trading on a positive note.

Related Views on News

PFIZER at All Time High; BSE HEALTHCARE Index Up 0.0% (Market Updates)

Aug 14, 2018 | Updated on Aug 14, 2018

PFIZER share price has hit an all time high at Rs 2,872 (up 1.0%). The BSE HEALTHCARE Index is up by 0.0%. Among the top gainers in the BSE HEALTHCARE Index today are PFIZER (up 1.0%) and SANOFI INDIA (up 1.0%). The top losers include GSK PHARMA and SHILPA MEDICARE (down 0.2%).

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Should You Buy These Mouthwatering High Dividend Stocks?(Profit Hunter)

Aug 1, 2018

Many stocks are yielding dividends even upwards of 4%-5%. Here are the kinds you should pick, and the ones to avoid.

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

NFO - Axis Equity Hybrid Fund: A Worthy Proposition?(Outside View)

Aug 1, 2018

PersonalFN explains if NFO: Axis Equity Hybrid Fund, would be a worthy proposition currently.

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 14, 2018 01:59 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS